Chronic Rhinosinusitis Clinical Trial
— AZI-CRSOfficial title:
Azithromycin as add-on Therapy in Patients Failing Medical and Surgical Treatment for Chronic Rhinosinusitis: a Double-blind, Randomized, Placebo-controlled Trial
Verified date | September 2016 |
Source | Centre hospitalier de l'Université de Montréal (CHUM) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Justification: Chronic rhinosinusitis (CRS) is one of the most common inflammatory diseases
with an incidence and prevalence superior to 10%. Unfortunately, more than 30% of patients do
not respond to standard medical and surgical treatment, thus continuously increasing the
symptomatologic and socio-economic burden of this disease.
Hypothesis: The investigators believe that the addition of azithromycin (AZI) to the
treatment regimen of patients with refractory CRS failing conventional medico-surgical
treatment will be beneficial in a symptomatologic and endoscopic level.
Primary objective: 1- To evaluate whether Azithromycine 250 mg PO three times weekly is
effective in controlling signs and symptoms of CRS in high-risk patients unresponsive to
standard management after endoscopic sinus surgery (ESS) with budesonide irrigations.
Secondary objectives:
i) Validate a simple and concise treatment algorithm for patients refractory to standard CRS
treatment of ESS and BUDI, with the addition of low-dose AZI.
ii) Characterise and define the population deemed "high-risk" for standard CRS treatment
failure by evaluating: 1) demographics, 2) inflammatory states and 3) the nasal flora
microbiome of patients at the different follow-up points of this study.
iii) Explore the mechanisms of AZI by assessing the changes in inflammatory states and the
nasal flora microbiome associated with successful AZI therapy.
Methods: Inclusion of all patients admitted for endoscopic sinus surgery (ESS) for CRS
operated by the same surgeon (MD). Following their first postoperative visit (2 weeks), all
patients will receive nasal irrigations with budesonide (BUDI) twice daily for 4 months and
will be re-evaluated. If there is a failure of treatment, patients eligible to receive AZI
will be randomized in to two groups, AZI 250mg or a placebo three times a week for 4 months.
At every follow-up, complete endoscopic exams will be performed, along with sinus cultures
and brush cytology.
Population: All patients deemed "high-risk" with CRS admitted for ESS between October 2014
and October 2015.
Status | Completed |
Enrollment | 129 |
Est. completion date | December 31, 2017 |
Est. primary completion date | August 15, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Patients with =1 of the following criteria: - history of sinus surgery, - first sinus surgery at =38 years of age, - an absolute eosinophilia of =500 cells/mm, - serum IgE levels of >150 kIU/L, - a Gram negative bacteria in a sinus culture, - the presence of intra-operative eosinophilic mucin. Exclusion Criteria: - Patients with cystic fibrosis, inverted papillomas, osteomata, mucoceles or other lesions of the base of skull will be excluded. - Patients with an elevated cardiovascular disease risk will be excluded from the randomized clinical trial part of this study. |
Country | Name | City | State |
---|---|---|---|
Canada | Centre Hospitalier de l'Université de Montréal (CHUM) | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Centre hospitalier de l'Université de Montréal (CHUM) | Pfizer |
Canada,
Desrosiers M, Evans GA, Keith PK, Wright ED, Kaplan A, Bouchard J, Ciavarella A, Doyle PW, Javer AR, Leith ES, Mukherji A, Robert Schellenberg R, Small P, Witterick IJ. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2011 May;40 Suppl 2:S99-193. Review. English, French. — View Citation
Desrosiers MY, Kilty SJ. Treatment alternatives for chronic rhinosinusitis persisting after ESS: what to do when antibiotics, steroids and surgery fail. Rhinology. 2008 Mar;46(1):3-14. Review. — View Citation
Maniakas A, Desrosiers M. Azithromycin add-on therapy in high-risk postendoscopic sinus surgery patients failing corticosteroid irrigations: A clinical practice audit. Am J Rhinol Allergy. 2014 Mar-Apr;28(2):151-5. doi: 10.2500/ajra.2013.27.4017. Epub 2013 Dec 13. — View Citation
Nader ME, Abou-Jaoude P, Cabaluna M, Desrosiers M. Using response to a standardized treatment to identify phenotypes for genetic studies of chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2010 Feb;39(1):69-75. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Signs and symptoms outcome to Azithromycin | Evaluate if Azithromycin 250mg by mouth, three times a week for four months will be effective in controlling signs and symptoms of chronic rhinosinusitis patients at a high-risk of recurrence following standard medical and surgical treatment. Disease level is evaluated through nasal endoscopy. | 4 months | |
Secondary | Treatment algorithm validation | Validate a simple and concise treatment algorithm for patients refractory to standard CRS treatment of ESS and BUDI, with the addition of low-dose AZI. | 8 months | |
Secondary | High-risk population | Characterise and define the population deemed "high-risk" for standard CRS treatment failure by evaluating: The demographics of this population The inflammatory state of patients at the different follow-ups (serum biomarkers) The microbiome of the nasal flora of patients at the different follow-ups (microbial cultures) |
12 months | |
Secondary | Azithromycin mechanism of action | Explore the mechanisms of action of AZI by assessing the changes in inflammatory states (serum biomarkers and epithelium inflammation) and the nasal flora microbiome (microbial cultures) associated with successful AZI therapy. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04131686 -
NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
|
||
Completed |
NCT02692794 -
Large Scale Cerebral Oximetry During Sinus Endoscopy
|
N/A | |
Completed |
NCT01988779 -
Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations
|
Phase 3 | |
Completed |
NCT01254916 -
The Sinonasal Outcome Test - 22, Validated for Danish Patients
|
N/A | |
Completed |
NCT03614923 -
Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
|
Phase 2 | |
Completed |
NCT03781804 -
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
|
Phase 3 | |
Completed |
NCT01198912 -
Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial
|
Phase 2 | |
Active, not recruiting |
NCT06457100 -
Esmolol Versus Lidocaine on the Quality of Postoperative Recovery in Patients Undergoing Functional Endoscopic Sinus Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT03280537 -
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps
|
Phase 3 | |
Terminated |
NCT02285283 -
Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps
|
Phase 2/Phase 3 | |
Completed |
NCT02218307 -
The Use of Antibiotic Sinonasal Rinse After Sinus Surgery
|
Phase 4 | |
Recruiting |
NCT01024075 -
Effect of Sinufoam-Dexamethasone Mixture on Post Endoscopic Sinus Surgery Outcomes
|
Phase 4 | |
Completed |
NCT01002313 -
Effect of Prednisone onTregs and TH17
|
Phase 1 | |
Completed |
NCT00396162 -
Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis
|
Phase 4 | |
Completed |
NCT03280550 -
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
|
Phase 3 | |
Recruiting |
NCT05935683 -
Rhinosinusitis Italian Network: the Italian Registry for Severe, Uncontrolled Chronic Rhinosinusitis
|
||
Completed |
NCT03478930 -
An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
|
Phase 3 | |
Completed |
NCT01943370 -
Early Saline Irrigation to Decrease Post-operative Endoscopic Debridement
|
N/A | |
Completed |
NCT02154555 -
A Randomized Controlled Trial Evaluating Postoperative Debridement Following Endoscopic Sinus Surgery
|
N/A | |
Completed |
NCT01778465 -
Effect of Dietary Salicylate in Aspirin Exacerbated Respiratory Disease
|
N/A |